UC San Diego Center for Microbiome Innovation (CMI) Announces Otsuka Pharmaceutical Development & Commercialization, Inc. as New Corporate Member

San Diego, Calif., June 20, 2019 - Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), has joined the UC San Diego Center for Microbiome Innovation (CMI) Industry Member board. Consistent with Otsuka’s nearly 100-year tradition, OPDC is dedicated to the research and clinical development of products that could have a major impact on human health with a focus on neuroscience, oncology, and nephrology therapeutic areas. The Center for Microbiome Innovation exists to inspire, nurture, and sustain vibrant collaborations between UC San Diego Microbiome experts and industry. The Center encompasses a large range of expertise in microbiome sampling, a broad range of technologies (metagenomics, metabolomics, metatranscriptomics) and data analysis using high-performance algorithms, machine learning, and modeling. The ultimate goal is to increase knowledge of the microbiome’s impact on human health and the environment with an eye to providing innovative solutions and treatment to major diseases as well as prolonging wellness. “OPDC is equally excited to join CMI’s Industry Member Board to better understand and gain insights into the gut-brain axis, and the potential impact on health outcomes for patients with serious mental illness and other chronic diseases.” said Deborah Profit, Vice President, Applied Innovation and Process Improvement, Otsuka Pharmaceutical Development & Commercialization. Click here to read the full release. (Please note that you will leave Otsuka-us.com)